A Crucial Role for Infected-Cell/Antibody Immune Complexes in the Enhancement of Endogenous Antiviral Immunity by Short Passive Immunotherapy

English version České info

Antiviral monoclonal antibodies (mAbs) represent promising therapeutics. However, most mAbs-based immunotherapies conducted so far have only considered the blunting of viral propagation and not other possible therapeutic effects independent of virus neutralization, namely the modulation of the endogenous immune response. As induction of long-term antiviral immunity still remains a paramount challenge for treating chronic infections, we have asked here whether neutralizing mAbs can, in addition to blunting viral propagation, exert immunomodulatory effects with protective outcomes. Supporting this idea, we report here that mice infected with the FrCas^E murine retrovirus on day 8 after birth die of leukemia within 4–5 months and mount a non-protective immune response, whereas those rapidly subjected to short immunotherapy with a neutralizing mAb survive healthy and mount a long-lasting protective antiviral immunity with strong humoral and cellular immune responses. Interestingly, the administered mAb mediates lysis of infected cells through an antibody-dependent cell cytotoxicity (ADCC) mechanism. In addition, it forms immune complexes (ICs) with infected cells that enhance antiviral CTL responses through FcγR-mediated binding to dendritic cells (DCs). Importantly, the endogenous antiviral antibodies generated in mAb-treated mice also display the same properties, allowing containment of viral propagation and enhancement of memory cellular responses after disappearance of the administered mAb. Thus, our data demonstrate that neutralizing antiviral mAbs can act as immunomodulatory agents capable of stimulating a protective immunity lasting long after the end of the treatment. They also show an important role of infected-cells/antibody complexes in the induction and the maintenance of protective immunity through enhancement of both primary and memory antiviral T-cell responses. They also indicate that targeting infected cells, and not just viruses, by antibodies can be crucial for elicitation of efficient, long-lasting antiviral T-cell responses. This must be considered when designing antiviral mAb-based immunotherapies.

Vyšlo v časopise: A Crucial Role for Infected-Cell/Antibody Immune Complexes in the Enhancement of Endogenous Antiviral Immunity by Short Passive Immunotherapy. PLoS Pathog 6(6): e32767. doi:10.1371/journal.ppat.1000948
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.ppat.1000948

Souhrn

Zdroje

1. ReichertJM

2007 Trends in the development and approval of monoclonal antibodies for viral infections. BioDrugs 21 1 7

2. MarascoWA

SuiJ

2007 The growth and potential of human antiviral monoclonal antibody therapeutics. Nat Biotechnol 25 1421 1434

3. TakadaA

EbiharaH

JonesS

FeldmannH

KawaokaY

2007 Protective efficacy of neutralizing antibodies against Ebola virus infection. Vaccine 25 993 999

4. OliphantT

NybakkenGE

EngleM

XuQ

NelsonCA

2006 Antibody recognition and neutralization determinants on domains I and II of West Nile Virus envelope protein. J Virol 80 12149 12159

5. HangartnerL

ZinkernagelRM

HengartnerH

2006 Antiviral antibody responses: the two extremes of a wide spectrum. Nat Rev Immunol 6 231 243

6. SuiJ

HwangWC

PerezS

WeiG

AirdD

2009 Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol 16 265 273

7. SimmonsCP

BernasconiNL

SuguitanAL

MillsK

WardJM

2007 Prophylactic and therapeutic efficacy of human monoclonal antibodies against H5N1 influenza. PLoS Med 4 e178

8. ZhuZ

ChakrabortiS

HeY

RobertsA

SheahanT

2007 Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies. Proc Natl Acad Sci U S A 104 12123 12128

9. WuH

PfarrDS

JohnsonS

BrewahYA

WoodsRM

2007 Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract. J Mol Biol 368 652 665

10. HongHJ

RyuCJ

HurH

KimS

OhHK

2004 In vivo neutralization of hepatitis B virus infection by an anti-preS1 humanized antibody in chimpanzees. Virology 318 134 141

11. GalunE

TerraultNA

ErenR

ZaubermanA

NussbaumO

2007 Clinical evaluation (Phase I) of a human monoclonal antibody against hepatitis C virus: safety and antiviral activity. J Hepatol 46 37 44

12. TrkolaA

KusterH

RusertP

von WylV

LeemannC

2008 In vivo efficacy of human immunodeficiency virus neutralizing antibodies: estimates for protective titers. J Virol 82 1591 1599

13. AkiyamaK

EbiharaS

YadaA

MatsumuraK

AibaS

2003 Targeting apoptotic tumor cells to Fc gamma R provides efficient and versatile vaccination against tumors by dendritic cells. J Immunol 170 1641 1648

14. SchuurhuisDH

van MontfoortN

Ioan-FacsinayA

JiawanR

CampsM

2006 Immune complex-loaded dendritic cells are superior to soluble immune complexes as antitumor vaccine. J Immunol 176 4573 4580

15. PortisJL

CzubS

GaronCF

McAteeFJ

1990 Neurodegenerative disease induced by the wild mouse ecotropic retrovirus is markedly accelerated by long terminal repeat and gag-pol sequences from nondefective Friend murine leukemia virus. J Virol 64 1648 1656

16. PincusSH

ColeR

IrelandR

McAteeF

FujisawaR

1995 Protective efficacy of nonneutralizing monoclonal antibodies in acute infection with murine leukemia virus. J Virol 69 7152 7158

17. PelegrinM

MarinM

OatesA

NoelD

SallerR

2000 Immunotherapy of a viral disease by in vivo production of therapeutic monoclonal antibodies. Hum Gene Ther 11 1407 1415

18. GrosL

DrejaH

FiserAL

PlaysM

PelegrinM

2005 Induction of long-term protective antiviral endogenous immune response by short neutralizing monoclonal antibody treatment. J Virol 79 6272 6280

19. LynchWP

CzubS

McAteeFJ

HayesSF

PortisJL

1991 Murine retrovirus-induced spongiform encephalopathy: productive infection of microglia and cerebellar neurons in accelerated CNS disease. Neuron 7 365 379

20. DrejaH

GrosL

VillardS

BachrachE

OatesA

2003 Monoclonal antibody 667 recognizes the variable region A motif of the ecotropic retrovirus CasBrE envelope glycoprotein and inhibits Env binding to the viral receptor. J Virol 77 10984 10993

21. McAteeFJ

PortisJL

1985 Monoclonal antibodies specific for wild mouse neurotropic retrovirus: detection of comparable levels of virus replication in mouse strains susceptible and resistant to paralytic disease. J Virol 56 1018 1022

22. GrosL

PelegrinM

MichaudHA

BiancoS

HernandezJ

2008 Endogenous cytotoxic T-cell response contributes to the long-term antiretroviral protection induced by a short period of antibody-based immunotherapy of neonatally infected mice. J Virol 82 1339 1349

23. GrosL

PelegrinM

PlaysM

PiechaczykM

2006 Efficient mother-to-child transfer of antiretroviral immunity in the context of preclinical monoclonal antibody-based immunotherapy. J Virol 80 10191 10200

24. GrohV

LiYQ

CiocaD

HunderNN

WangW

2005 Efficient cross-priming of tumor antigen-specific T cells by dendritic cells sensitized with diverse anti-MICA opsonized tumor cells. Proc Natl Acad Sci U S A 102 6461 6466

25. CorbinA

PratsAC

DarlixJL

SitbonM

1994 A nonstructural gag-encoded glycoprotein precursor is necessary for efficient spreading and pathogenesis of murine leukemia viruses. J Virol 68 3857 3867

26. SitbonM

SolaB

EvansL

NishioJ

HayesSF

1986 Hemolytic anemia and erythroleukemia, two distinct pathogenic effects of Friend MuLV: mapping of the effects to different regions of the viral genome. Cell 47 851 859

27. BergthalerA

FlatzL

VerschoorA

HegazyAN

HoldenerM

2009 Impaired Antibody Response Causes Persistence of Prototypic T Cell-Contained Virus. PLoS Biol 7 e80

28. LavilletteD

MoriceY

GermanidisG

DonotP

SoulierA

2005 Human serum facilitates hepatitis C virus infection, and neutralizing responses inversely correlate with viral replication kinetics at the acute phase of hepatitis C virus infection. J Virol 79 6023 6034

29. PestkaJM

ZeiselMB

BlaserE

SchurmannP

BartoschB

2007 Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Proc Natl Acad Sci U S A 104 6025 6030

30. PinschewerDD

PerezM

JeetendraE

BachiT

HorvathE

2004 Kinetics of protective antibodies are determined by the viral surface antigen. J Clin Invest 114 988 993

31. WeissR

TeichN

VarmusH

CoffinJ

1985 RNA Tumor Viruses. Cold Spring Harbor, NY Cold Spring Harbor Laboratory

32. StromnesIM

DittmerU

SchumacherTN

SchepersK

MesserRJ

2002 Temporal effects of gamma interferon deficiency on the course of Friend retrovirus infection in mice. J Virol 76 2225 2232

33. ChenW

QinH

ChesebroB

CheeverMA

1996 Identification of a gag-encoded cytotoxic T-lymphocyte epitope from FBL-3 leukemia shared by Friend, Moloney, and Rauscher murine leukemia virus-induced tumors. J Virol 70 7773 7782

34. OhlenC

KalosM

ChengLE

ShurAC

HongDJ

2002 CD8(+) T cell tolerance to a tumor-associated antigen is maintained at the level of expansion rather than effector function. J Exp Med 195 1407 1418

35. KurlanderRJ

EllisonDM

HallJ

1984 The blockade of Fc receptor-mediated clearance of immune complexes in vivo by a monoclonal antibody (2.4G2) directed against Fc receptors on murine leukocytes. J Immunol 133 855 862

36. SchuurhuisDH

Ioan-FacsinayA

NagelkerkenB

van SchipJJ

SedlikC

2002 Antigen-antibody immune complexes empower dendritic cells to efficiently prime specific CD8+ CTL responses in vivo. J Immunol 168 2240 2246

37. BalkowS

KruxF

LoserK

BeckerJU

GrabbeS

2007 Friend retrovirus infection of myeloid dendritic cells impairs maturation, prolongs contact to naive T cells, and favors expansion of regulatory T cells. Blood 110 3949 3958

38. BradyLJ

2005 Antibody-mediated immunomodulation: a strategy to improve host responses against microbial antigens. Infect Immun 73 671 678

39. CarterRH

FearonDT

1992 CD19: lowering the threshold for antigen receptor stimulation of B lymphocytes. Science 256 105 107

40. HeymanB

2000 Regulation of antibody responses via antibodies, complement, and Fc receptors. Annu Rev Immunol 18 709 737

41. SongH

NieX

BasuS

CernyJ

1998 Antibody feedback and somatic mutation in B cells: regulation of mutation by immune complexes with IgG antibody. Immunol Rev 162 211 218

42. WuY

SukumarS

El ShikhME

BestAM

SzakalAK

2008 Immune complex-bearing follicular dendritic cells deliver a late antigenic signal that promotes somatic hypermutation. J Immunol 180 281 290

43. HamanoY

AraseH

SaishoH

SaitoT

2000 Immune complex and Fc receptor-mediated augmentation of antigen presentation for in vivo Th cell responses. J Immunol 164 6113 6119

44. DhodapkarKM

KrasovskyJ

WilliamsonB

DhodapkarMV

2002 Antitumor monoclonal antibodies enhance cross-presentation ofcCellular antigens and the generation of myeloma-specific killer T cells by dendritic cells. J Exp Med 195 125 133

45. RafiqK

BergtoldA

ClynesR

2002 Immune complex-mediated antigen presentation induces tumor immunity. J Clin Invest 110 71 79

46. YaoX

ZhengB

ZhouJ

XuDZ

ZhaoK

2007 Therapeutic effect of hepatitis B surface antigen-antibody complex is associated with cytolytic and non-cytolytic immune responses in hepatitis B patients. Vaccine 25 1771 1779

47. VillingerF

MayneAE

BostikP

MoriK

JensenPE

2003 Evidence for antibody-mediated enhancement of simian immunodeficiency virus (SIV) Gag antigen processing and cross presentation in SIV-infected rhesus macaques. J Virol 77 10 24

48. HaigwoodNL

MontefioriDC

SuttonWF

McClureJ

WatsonAJ

2004 Passive immunotherapy in simian immunodeficiency virus-infected macaques accelerates the development of neutralizing antibodies. J Virol 78 5983 5995

49. RegnaultA

LankarD

LacabanneV

RodriguezA

TheryC

1999 Fcgamma receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization. J Exp Med 189 371 380

50. FrankiSN

StewardKK

BettingDJ

KafiK

YamadaRE

2008 Dendritic cells loaded with apoptotic antibody-coated tumor cells provide protective immunity against B-cell lymphoma in vivo. Blood 111 1504 1511

51. SelenkoN

MajdicO

JagerU

SillaberC

StocklJ

2002 Cross-priming of cytotoxic T cells promoted by apoptosis-inducing tumor cell reactive antibodies? J Clin Immunol 22 124 130

52. VasovicLV

DyallR

ClynesRA

RavetchJV

Nikolic-ZugicJ

1997 Synergy between an antibody and CD8+ cells in eliminating an established tumor. Eur J Immunol 27 374 382

53. BachmannMF

HunzikerL

ZinkernagelRM

StorniT

KopfM

2004 Maintenance of memory CTL responses by T helper cells and CD40-CD40 ligand: antibodies provide the key. Eur J Immunol 34 317 326

54. GallimoreA

GlitheroA

GodkinA

TissotAC

PluckthunA

1998 Induction and exhaustion of lymphocytic choriomeningitis virus-specific cytotoxic T lymphocytes visualized using soluble tetrameric major histocompatibility complex class I-peptide complexes. J Exp Med 187 1383 1393

55. ValmoriD

LevyF

GodefroyE

ScottoL

SouleimanianNE

2007 Epitope clustering in regions undergoing efficient proteasomal processing defines immunodominant CTL regions of a tumor antigen. Clin Immunol 122 163 172

56. HammerSM

EronJJJr

ReissP

SchooleyRT

ThompsonMA

2008 Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. Jama 300 555 570

57. DeutschM

HadziyannisSJ

2008 Old and emerging therapies in chronic hepatitis C: an update. J Viral Hepat 15 2 11

58. AiutiF

MezzaromaI

2006 Failure to reconstitute CD4+ T-cells despite suppression of HIV replication under HAART. AIDS Rev 8 88 97

59. ElrefaeiM

McElroyMD

PreasCP

HohR

DeeksS

2004 Central memory CD4+ T cell responses in chronic HIV infection are not restored by antiretroviral therapy. J Immunol 173 2184 2189

60. PitcherCJ

QuittnerC

PetersonDM

ConnorsM

KoupRA

1999 HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression. Nat Med 5 518 525

61. ZinkernagelRM

2003 On natural and artificial vaccinations. Annu Rev Immunol 21 515 546

62. SitbonM

NishioJ

WehrlyK

LodmellD

ChesebroB

1985 Use of a focal immunofluorescence assay on live cells for quantitation of retroviruses: distinction of host range classes in virus mixtures and biological cloning of dual-tropic murine leukemia viruses. Virology 141 110 118

63. SchepersK

ToebesM

SotthewesG

Vyth-DreeseFA

DellemijnTA

2002 Differential kinetics of antigen-specific CD4+ and CD8+ T cell responses in the regression of retrovirus-induced sarcomas. J Immunol 169 3191 3199

64. LutzMB

KukutschN

OgilvieAL

RossnerS

KochF

1999 An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods 223 77 92

65. GuyreCA

GomesD

SmithKA

KaplanJM

PerriconeMA

2008 Development of an in vivo antibody-mediated killing (IVAK) model, a flow cytometric method to rapidly evaluate therapeutic antibodies. J Immunol Methods 333 51 60

66. LeeGM

FongS

FrancisK

OhDJ

PalssonBO

2000 In situ labeling of adherent cells with PKH26. In Vitro Cell Dev Biol Anim 36 4 6